OraSure Technologies, Inc. (NASDAQ:OSUR - Get Free Report) CEO Manner Carrie Eglinton acquired 78,625 shares of OraSure Technologies stock in a transaction that occurred on Thursday, February 27th. The stock was acquired at an average price of $3.15 per share, with a total value of $247,668.75. Following the completion of the acquisition, the chief executive officer now directly owns 1,259,664 shares in the company, valued at $3,967,941.60. This represents a 6.66 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
OraSure Technologies Stock Up 2.6 %
NASDAQ:OSUR traded up $0.09 on Monday, hitting $3.57. The stock had a trading volume of 1,153,365 shares, compared to its average volume of 959,187. OraSure Technologies, Inc. has a 52-week low of $2.68 and a 52-week high of $7.43. The stock has a market cap of $266.30 million, a price-to-earnings ratio of 23.80 and a beta of 0.05. The business's 50-day simple moving average is $3.78 and its two-hundred day simple moving average is $4.00.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its stake in shares of OraSure Technologies by 202.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 5,234 shares in the last quarter. Causeway Capital Management LLC bought a new position in shares of OraSure Technologies in the fourth quarter worth about $36,000. Raymond James Financial Inc. purchased a new position in shares of OraSure Technologies during the 4th quarter valued at about $37,000. Boothbay Fund Management LLC purchased a new stake in OraSure Technologies in the 4th quarter worth approximately $42,000. Finally, Gotham Asset Management LLC purchased a new stake in OraSure Technologies in the 4th quarter worth approximately $43,000. 93.50% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Separately, StockNews.com cut shares of OraSure Technologies from a "buy" rating to a "hold" rating in a report on Saturday, February 22nd.
Get Our Latest Report on OraSure Technologies
About OraSure Technologies
(
Get Free Report)
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Featured Articles
Before you consider OraSure Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OraSure Technologies wasn't on the list.
While OraSure Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
